Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975508 | 0.86 | TSHR (0.60) | MAPK1TSHRCA1CA2CA12 | |
| SCHEMBL22838421 | 0.85 | MAPT (0.53) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13895732 | 0.84 | MAPK1 (0.59) | MAPK1BPTFTSHRCYP1A2CYP3A4 | |
| SCHEMBL22838539 | 0.82 | SMPD1 (0.53) | MAPK1 | |
| SCHEMBL22838565 | 0.82 | TAS1R3 (0.47) | MAPK1TSHRALDH1A1 | |
| SCHEMBL22838506 | 0.79 | ROCK2 (0.55) | HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL4280677 | 0.78 | MAPK1 (0.90) | MAPK1BPTFTSHRCYP1A2CYP3A4 | |
| SCHEMBL6944861 | 0.76 | MAPK1 (1.00) | MAPK1BPTFTSHRCYP1A2CYP3A4 | |
| SCHEMBL335681 | 0.76 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29415167 | 0.76 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368899-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368899-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1351/4885BPTF 367/4885TSHR 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.